Semustine
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06809712 | Aug 2022 → Oct 2026 expected | hematologic disorder | He Huang | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07677306 | Jul 2026 → Dec 2027 expected | myelodysplastic syndrome | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03412266 | Feb 2018 → Mar 2023 | myelodysplastic syndrome | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03412409 | Feb 2018 → Sep 2025 | acute leukemia, myelodysplastic syndrome | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07583888 | May 2026 → Aug 2027 expected | acute myeloid leukemia, disease related to hematopoietic stem cell transplant | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00427570 | Sep 1977 → May 2006 | colorectal cancer | NSABP Foundation Inc | Completed | No outcome recorded |
Also used as a comparator or background therapy in 10 trials
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Semustine | “RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4),...” NCT03412266 ↗15“Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d” NCT04880746 ↗ “semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.” NCT05504603 ↗ “semustine (Me-CCNU, 250 mg·m-2), orally once on day -3” NCT03799224 ↗ “semustine (Me-CCNU, 250 mg·m-2), orally once on day -3” NCT03793517 ↗ “Semustine: 250 mg/m² orally once on day -10.” NCT07583888 ↗ “semustine 250 mg/m²/day on day -9;” NCT03256071 ↗ “semustine 250 mg/m² on day -8” NCT07562568 ↗ “semustine (250 mg/m2, orally)” PMID 33718234 ↗ Feb 2021 “semustine 250 mg/m² on day -8” NCT07575412 ↗ “semustine (250 mg/m2, day-3)” NCT07677306 ↗ |
| Known as | 1-(2-chloroethyl)-3-(4-trans-methylcyclohexyl)-1-nitrosourea | “1-(2-chloroethyl)-3-(4-trans-methylcyclohexyl)-1-nitrosourea (i.e., MeCCNU or semustine), vincristine, and 5-fluorouracil was associated with better 5-year disease-free and...” PMID 15292384 ↗ Aug 2004 |
| Known as | ICIG 1110 | ChEMBL registry synonym — accepted as the source's own label CHEMBL12948 ↗ |
| Known as | Me-CCNU | “1-(2-chloroethyl)-3-(4-trans-methylcyclohexyl)-1-nitrosourea (i.e., MeCCNU or semustine), vincristine, and 5-fluorouracil was associated with better 5-year disease-free and...” PMID 15292384 ↗ Aug 20044“semustine (Me-CCNU, 250 mg·m-2), orally once on day -3” NCT03793517 ↗ “semustine (Me-CCNU, 250 mg·m-2), orally once on day -3” NCT03799224 ↗ “Semustine (MeCCNU)” NCT06809699 ↗ “Semustine (MeccNU)” NCT06809712 ↗ |
| Known as | Methyl lomustine | ChEMBL registry synonym — accepted as the source's own label CHEMBL12948 ↗ |
| Known as | Methyl-CCNU | “5-Fluorouracil, 5-FU, NSC-19893; Methyl-CCNU, MeCCNU, NSC-95441; Vincristine, VCR, NSC-67574.” NCT00427570 ↗ |
| Known as | NSC-758471 | ChEMBL registry synonym — accepted as the source's own label CHEMBL12948 ↗ |
| Known as | NSC-95441 | “5-Fluorouracil, 5-FU, NSC-19893; Methyl-CCNU, MeCCNU, NSC-95441; Vincristine, VCR, NSC-67574.” NCT00427570 ↗ |
| Known as | Semustina | ChEMBL registry synonym — accepted as the source's own label CHEMBL12948 ↗ |
| Modality | Small molecule | — CHEMBL12948 ↗ |
| Route | Oral | “Semustine orally once every 28 days” NCT00335075 ↗ |